Resumen

LUGO, SM; CAMACHO, ME; MONTOYA, YC  y  VIVAS, SC. Psoriasis during treatment with Natalizumab in multiple sclerosis patient. Rev. argent. dermatol. [online]. 2018, vol.99, n.2, pp.1-10. ISSN 1851-300X.

The prevalence of psoriasis among  patients  with multiple sclerosis  ranges from 1.59 to 7.7%. They share genetic and pathogenic characteristics where the main role is fulfilled by T lymphocytes (Th1-Th17), its activation triggers the release of proinflammatory  cytokines, favoring  the  development  of  inflammatory  events characteristic of both entities. Natalizumab, used in the treatment of patients with multiple sclerosis can trigger psoriasis, blocking some of the adhesion molecules or inflammatory pathways, which can be compensate by other pathways, and produce paradoxical immune reactions.

Palabras clave : psoriasis; multiple sclerosis; natalizumab.